Last updated: March 2, 2026
What Is NDC 00002-4184?
NDC 00002-4184 corresponds to Rituxan (rituximab), a monoclonal antibody indicated for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune diseases. It is marketed by Genentech, a Roche company.
Market Size and Demand Drivers
Key Indications
- Non-Hodgkin lymphoma (NHL): The primary driver, representing roughly 70% of Rituxan's revenue.
- Chronic lymphocytic leukemia (CLL)
- Rheumatoid arthritis (RA)
- Granulomatosis with polyangiitis (GPA)
- Microscopic polyangiitis (MPA)
Market Size Estimates
- The global NHL treatment market was valued at USD 27 billion in 2022.
- Rituxan holds a dominant market share, estimated at 40-45%, translating to USD 10-12 billion annually.
- The CLL and RA markets contribute an additional USD 3-6 billion combined.
Competitive Landscape
- Biosimilars launched in select markets since 2021.
- Key competitors include biosimilars such as Truxima (product of Celltrion), Ruxience (Samsung Bioepis), and others.
- Patent protections primarily expired in Europe and the US in 2018-2019, leading to increased biosimilar penetration.
Geographic Market Dynamics
- North America accounts for over 50% of sales.
- Europe represents around 25-30%.
- Other regions, notably Asia-Pacific and Latin America, exhibit growing access and demand.
Price Trends and Projections
Current Pricing
- In the US, Ristuxan retail list price approaches USD 6,000-7,000 per infusion dose.
- Per-vial acquisition costs (wholesaler discounts applied) average USD 2,500-3,000.
- Biosimilars, where available, are priced roughly 20-35% below the original.
Price Changes Over the Past Three Years
| Year |
US List Price (USD) |
Biosimilar Price (USD) |
Market Share of Biosimilars |
| 2020 |
6,921 |
4,500 - 5,000 |
5% |
| 2021 |
6,900 - 7,000 |
4,200 - 4,800 |
15% |
| 2022 |
6,950 - 7,000 |
3,900 - 4,500 |
30% |
Future Price Projections (2023-2028)
- Biosimilar market penetration is expected to reach 50-60% in the US by 2025.
- List prices are likely to stabilize or decline slightly, given increased competition.
- Wholesale acquisition cost for the originator could fall to USD 5,500-6,000 per dose by 2025.
Impact of Biosimilars and Market Competition
- Entry of biosimilars reduces the price of Rituxan by an estimated 20-35%.
- Patent litigations and market exclusivity challenges may influence timing; patent expiry of key patents is projected for 2023-2025.
Revenue and Price Forecasts
| Year |
Total US Revenue (USD billions) |
Average Price of Rituxan (USD per dose) |
Biosimilar Market Share (%) |
| 2023 |
2.5 |
6,800 |
40% |
| 2024 |
2.3 |
6,600 |
50% |
| 2025 |
2.1 |
6,200 |
60% |
Note: These projections assume continued demand growth in established indications and biosimilar adoption.
Key Market Risks and Opportunities
Risks
- Patent litigation delays biosimilar market entry.
- Pricing pressure from biosimilars and potential reimbursement restrictions.
- Regulation and approval delays in emerging markets.
Opportunities
- Expansion into new indications such as autoimmune diseases.
- Strategic partnerships and license agreements.
- Increased global access, especially in emerging markets.
Key Takeaways
- Rituxan remains a leading therapy for hematologic and autoimmune conditions, with USD 10-12 billion annual global sales.
- Biosimilars are rapidly gaining market share, pushing prices downward.
- US prices could decline an additional 15-20% through 2025.
- Patent expiry is a critical factor influencing market dynamics and pricing.
- Future growth hinges on market expansion, biosimilar competition, and regulatory developments.
FAQs
Q1: When will biosimilar competition significantly impact Rituxan pricing?
A1: Biosimilar market penetration is expected to reach 50-60% by 2025, leading to notable price reductions.
Q2: How much can Rituxan prices decline post-biosimilar entry?
A2: Prices are likely to fall by 20-35%, with the US average per-dose price declining to USD 5,500-6,000 by 2025.
Q3: What regions present the greatest growth opportunity?
A3: Emerging markets in Asia-Pacific and Latin America, due to increasing healthcare access and demand.
Q4: What are the main risks to revenue growth?
A4: Patent disputes, reimbursement restrictions, and aggressive biosimilar competition.
Q5: How does the patent expiry influence future revenues?
A5: Patent expiry in 2023-2025 will facilitate biosimilar entry, leading to price reductions and increased market share for lower-cost options.
References
[1] IQVIA. (2022). Pharmaceutical Market Trends.
[2] EvaluatePharma. (2022). Global Oncology Market Data.
[3] FDA. (2019). Biosimilar Guidance and Patent Data.
[4] U.S. Food & Drug Administration. (2018). Rituxan Labeling and Indications.
[5] Sandoz. (2022). Biosimilar Portfolio.
